Marimastat

ALTERNATE NAME: (2S,3R)-N4-{[1(S)-2,2-Dimethyl-1-\[(methylamino)carbonyl]propyl]-N1,2-dihydroxy-3-(2-methylpropyl)butanediamide; BB-2516; TA-2516; Marimistat

CATALOG #: 1790-1,5

AMOUNT: 1 mg, 5 mg

STRUCTURE:

FOUR RESEARCH USE ONLY! Not to be used on humans.

RELATED PRODUCTS:
- AEBSF, HCl (Cat. No. 1644-200, 1G)
- Aprotinin (Cat. No. 4690-5, 100, 1000)
- Batimastat (Cat. No. 1704-1)
- E-64 (Cat. No. 1739-5, 25)
- clasto-Lactacystin-β-lactone (Cat. No. 1710-100)
- Lactacystin (Cat. No. 1709-200)
- Leupeptin, Hemisulfate (Cat. No. 1648-25, 50, 100)
- MG-132 (Cat. No. 1709-5)
- Nafamostat Mesylate (Cat. No. 1760-10, 50)
- PMSF (Cat. No. 1548-5)
- Pepstatin A (Cat. No. 1732-25, 100)

MOLECULAR FORMULA: C_{15}H_{29}N_{3}O_{5}

MOLECULAR WEIGHT: 331.41

CAS NUMBER: 154039-60-8

APPEARANCE: White solid

SOLUBILITY: DMSO (100 mM)

PURITY: ≥98% by HPLC

STORAGE: Store at -20 °C

DESCRIPTION: A broad spectrum matrix metalloprotease (MMP) inhibitor with IC_{50} values of 3, 5, 6, 9 and 13 nM for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 respectively. It covalently binds to the zinc(II) ion in the active site of MMPs, thereby inhibiting the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.


HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.